摘要
目的探讨胃癌组织中SIRT1、β-catenin的表达水平及其与临床病理特征的相关性。方法采用免疫组织化学方法对101例胃癌组织SIRT1、β-catenin的表达进行检测,分析其与肿瘤临床病理特征的相关性。结果胃癌组织中SIRT1、β-catenin阳性表达率分别为64.4%(65/101)和47.5%(48/101)。SIRT1在肠型胃癌中的表达显著高于弥漫型胃癌中的表达,P<0.05;SIRT1的高表达与胃癌发生部位、肿瘤大小、淋巴结转移情况及β-catenin的表达之间的差异无统计学意义(P>0.05),SIRT1表达与β-catenin的表达无相关性(r=0.01;P=0.751)。结论 SIRT1可能参与了胃癌的发生。
Objective To investigate the expression of SIRT1 and β-catenin in gastric cancer. Methods Immunohistochemieal method was used to detect the expressions of SIRT1 and β-catenin in 101 samples of gastric cancer. Results The SIRT1 and β-catenin expressions respectively were 64.4% （65/101 ） and 47.5% （48/101）. Statistically,the expressions of SIRT1 in intestinal type gastric cancer were significantly higher than those in diffuse type gastric cancer / P 〈 0.05 ）. Altered expression of SIRT1 was not associated with clinicopathological parameters, including tumor location, size and lymph node metastasis （ P 〉 0. 05 ）. There was no significant cor- relation between SIRT1 and β-eatenin expression （ r = 0. 01 ,P = 0.751 ）. Conclusion The upregulation of SIRT1 may play a possible role in gastric carcinogenesis.
出处
《滨州医学院学报》
2013年第2期94-96,共3页
Journal of Binzhou Medical University
基金
山东省自然科学基金(No.ZR2012HL32)
滨州医学院科研启动基金项目(No.BY2010KYQD10)
